Skip to content

Opko Health OPK Transfer Of Intellectual Property And Other — Upfront Payment

Similar metrics at other companies

Praxis Precision Medicines, Inc. logo
PRAXLicense — Upfront payment
$0
EyePoint, Inc.
 logo
EYPTProduct Rights Agreement — Upfront Cash Payment
$75M0.0%
Harmony Biosciences Holdings, Inc. logo
HRMYPayment Of Upfront Fee Investing Activities
$32M+753%
Ionis Pharmaceuticals logo
IONSUpfront Royalty Payment Received
$500M
Septerna, Inc. logo
SEPNMaterial Right — Non Refundable One Time Upfront Payment Received
$41.2M+300%
Septerna, Inc. logo
SEPNCollaboration Milestones — Non Refundable One Time Upfront Payment Received
$500K

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B-22.4%
P/S1.9×-0.2×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept opk:UpfrontPayment.

The official record: Opko Health’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's transfer of intellectual property and other — upfront payment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's transfer of intellectual property and other — upfront payment?
Opko Health (OPK) reported transfer of intellectual property and other — upfront payment of $1.75M in Q4 2025.
What does transfer of intellectual property and other — upfront payment mean?
This represents non-refundable cash payments received at the inception of a licensing or collaboration agreement for intellectual property. These payments are critical indicators of the perceived market value of the company's early-stage assets and provide immediate liquidity to fund ongoing development. A high volume of such payments suggests strong demand for the company's proprietary technology.